Simple Summary The median age of diagnosis of dementia, as well as for many cancers, is
above 60 years. Dementia should not exclude even frail, elderly patients from cancer …

Alzheimer's disease (AD) encompasses a long continuum from a preclinical phase,
characterized by neuropathological alterations albeit normal cognition, to a symptomatic …

Pupil dynamics has emerged as a critical non-invasive indicator of brain state changes. In
particular, pupillary-light-responses (PLR) in Alzheimer's disease (AD) patients show …

Alzheimer's disease (AD) is a complex neurodegenerative disorder that has impacted
millions of people worldwide. The neuroanatomical heterogeneity of AD has made it …

Co-occurrence of beta amyloid (Aβ) and white matter hyperintensities (WMHs) increase the
risk of dementia and both are considered biomarkers of preclinical dementia. Moderation …

Purpose The pathological hallmarks of Alzheimer's disease (AD), amyloid, tau, and
associated neurodegeneration, are present in the cortical gray matter (GM) years before …

The early accumulation of AD pathology such as Aβ and tau in cognitively normal older
people is predictive of cognitive decline, but it has been difficult to dissociate the cognitive …

Background: It is difficult to assess brain health status and risk of cognitive impairment,
particularly at the initial evaluation. To address this, we developed the Brain Health Platform …

Background Amyloid-beta (Aβ) plaque is a neuropathological hallmark of Alzheimer's
disease (AD). As anti-amyloid monoclonal antibodies enter the market, predicting brain …

Alzheimer's disease (AD) is a neurodegenerative disease that is characterized by amyloid
plaques, neurofibrillary tangles, and neuronal loss. Early cerebral and body iron …